Takeo Nakajima1, Tatsuya Nagano2, Yoshihiro Nishimura3. 1. Nakajima Medical Clinic, Kobe, Japan. 2. Division of Respiratory Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine, Kobe, Japan tnagano@med.kobe-u.ac.jp. 3. Division of Respiratory Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine, Kobe, Japan.
Abstract
BACKGROUND/AIM: Although the usefulness of inhaled corticosteroids and long-acting β2 agonists (ICS/LABA) in cough-variant asthma and cough-predominant asthma has been reported, there is no consensus on its starting dose. The aim of this study is to find the optimal dose of ICS/LABA for cough-variant asthma and cough-predominant asthma. PATIENTS AND METHODS: We analysed 112 patients who visited our clinic from January 2009 to December 2012 with the chief complaint of cough that had continued for more than 3 weeks. Cough-variant asthma (n=30) and cough-predominant asthma (n=7) were treated with ICS/LABA. RESULTS: There was no significant difference in cough duration time from starting ICS/LABA in cough-variant asthma and cough-predominant asthma between medium and high doses (14.3% versus 10.9%, respectively) (p=0.192). Moreover, there was no significant difference in cough duration time from starting ICS/LABA in cough-variant asthma between medium and high doses (13.2% versus 11.5%, respectively) (p=0.433). CONCLUSION: The medium starting dose of ICS/LABA is sufficient for treating cough-variant asthma.
BACKGROUND/AIM: Although the usefulness of inhaled corticosteroids and long-acting β2 agonists (ICS/LABA) in cough-variant asthma and cough-predominant asthma has been reported, there is no consensus on its starting dose. The aim of this study is to find the optimal dose of ICS/LABA for cough-variant asthma and cough-predominant asthma. PATIENTS AND METHODS: We analysed 112 patients who visited our clinic from January 2009 to December 2012 with the chief complaint of cough that had continued for more than 3 weeks. Cough-variant asthma (n=30) and cough-predominant asthma (n=7) were treated with ICS/LABA. RESULTS: There was no significant difference in cough duration time from starting ICS/LABA in cough-variant asthma and cough-predominant asthma between medium and high doses (14.3% versus 10.9%, respectively) (p=0.192). Moreover, there was no significant difference in cough duration time from starting ICS/LABA in cough-variant asthma between medium and high doses (13.2% versus 11.5%, respectively) (p=0.433). CONCLUSION: The medium starting dose of ICS/LABA is sufficient for treating cough-variant asthma.
Authors: Bo Lundbäck; Eva Rönmark; Anne Lindberg; Ann-Christin Jonsson; Lars-Gunnar Larsson; Frank Pétavy; Mark James Journal: Respir Med Date: 2005-10-21 Impact factor: 3.415
Authors: M Kavuru; J Melamed; G Gross; C Laforce; K House; B Prillaman; L Baitinger; A Woodring; T Shah Journal: J Allergy Clin Immunol Date: 2000-06 Impact factor: 10.793
Authors: Richard Beasley; James Harper; Grace Bird; Ingrid Maijers; Mark Weatherall; Ian D Pavord Journal: Am J Respir Crit Care Med Date: 2019-06-15 Impact factor: 21.405
Authors: M Dąbrowska; E M Grabczak; M Arcimowicz; A Domeracka-Kołodziej; J Domagała-Kulawik; R Krenke; M Maskey-Warzęchowska; B Tarchalska; R Chazan Journal: Adv Exp Med Biol Date: 2015 Impact factor: 2.622